Pharmacokinetics and Safety of a Single Oral Dose of Peficitinib (ASP015K) in Japanese Subjects With Normal and Impaired Hepatic Function-Reference-Cited by-同舟云学术

Pharmacokinetics and Safety of a Single Oral Dose of Peficitinib (ASP015K) in Japanese Subjects With Normal and Impaired Hepatic Function

Published:2019-12-12 Issue:6 Volume:9 Page:699-708
ISSN:2160-763X
Container-title:Clinical Pharmacology in Drug Development
language:en
Short-container-title:Clinical Pharmacology in Drug Development

Author:

Miyatake Daisuke¹,Shibata Tomohisa¹,Toyoshima Junko¹,Kaneko Yuichiro¹,Oda Kazuo²,Nishimura Tetsuya¹,Katashima Masataka¹,Sakaki Masashi³,Inoue Kazuaki⁴,Ito Takayoshi⁵,Uchida Naoki⁶,Furihata Kenichi⁷,Urae Akinori⁸

Affiliation:

1. Astellas Pharma Inc Tokyo Japan

2. Astellas Research Institute of America LLC Northbrook Illinois USA

3. Showa University School of Medicine Tokyo Japan

4. Showa University Fujigaoka Hospital Yokohama Japan

5. Showa University Koto Toyosu Hospital Tokyo Japan

6. Clinical Research Institute of Clinical Pharmacology and Therapeutics Showa University Tokyo Japan

7. P‐One Clinic Keikokai Medical Corporation Tokyo Japan

8. Mediscience Planning, Inc Tokyo Japan

Publisher

Wiley

Subject

Pharmacology (medical),Pharmaceutical Science

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cpdd.751

Reference26 articles.

1. Efficacy and safety of the oral Janus kinase inhibitor peficitinib (ASP015K) monotherapy in patients with moderate to severe rheumatoid arthritis in Japan: a 12-week, randomised, double-blind, placebo-controlled phase IIb study

2. Discovery and structural characterization of peficitinib (ASP015K) as a novel and potent JAK inhibitor

3. JAK3-selective inhibitor peficitinib for the treatment of rheumatoid arthritis

4. Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases

5. Progress in understanding the safety and efficacy of Janus kinase inhibitors for treatment of rheumatoid arthritis

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Janus Kinases and Autoimmunity: Bridging Pathways to Therapy;International Journal of Drug Discovery and Pharmacology;2024-06-05

2. Pacritinib inhibits proliferation of primary effusion lymphoma cells and production of viral interleukin-6 induced cytokines;Scientific Reports;2024-02-19

3. Safety and effectiveness of peficitinib 100 mg/day in patients achieving clinical remission from a long-term open-label extension study in Japan, Korea, and Taiwan (RAJ2);Modern Rheumatology;2023-12-07

4. Regulation of the JAK/STAT signaling pathway: The promising targets for cardiovascular disease;Biochemical Pharmacology;2023-07

5. A Comprehensive Overview of Globally Approved JAK Inhibitors;Pharmaceutics;2022-05-06